BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 33890170)

  • 1. Determination of Tumor Dose Response Thresholds in Patients with Chemorefractory Intrahepatic Cholangiocarcinoma Treated with Resin and Glass-based Y90 Radioembolization.
    Cheng B; Villalobos A; Sethi I; Wagstaff W; Galt J; Brandon D; Schuster DM; Bercu Z; Majdalany B; Kokabi N
    Cardiovasc Intervent Radiol; 2021 Aug; 44(8):1194-1203. PubMed ID: 33890170
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Nezami N; Kokabi N; Camacho JC; Schuster DM; Xing M; Kim HS
    Nucl Med Biol; 2018 Apr; 59():22-28. PubMed ID: 29448165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis.
    Garin E; Rolland Y; Edeline J; Icard N; Lenoir L; Laffont S; Mesbah H; Breton M; Sulpice L; Boudjema K; Rohou T; Raoul JL; Clement B; Boucher E
    J Nucl Med; 2015 Mar; 56(3):339-46. PubMed ID: 25678490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of 3 Different Therapeutic Particles in Radioembolization of Locally Advanced Intrahepatic Cholangiocarcinoma.
    Wagemans MEHM; Kunnen B; Stella M; van Rooij R; Smits M; Bruijnen R; Lam MGEH; de Jong HWAM; Braat AJAT
    J Nucl Med; 2024 Feb; 65(2):272-278. PubMed ID: 38176716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Voxel-based dosimetry predicting treatment response and related toxicity in HCC patients treated with resin-based Y90 radioembolization: a prospective, single-arm study.
    Kokabi N; Arndt-Webster L; Chen B; Brandon D; Sethi I; Davarpanahfakhr A; Galt J; Elsayed M; Bercu Z; Cristescu M; Kappadath SC; Schuster DM
    Eur J Nucl Med Mol Imaging; 2023 May; 50(6):1743-1752. PubMed ID: 36650357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival.
    Hoffmann RT; Paprottka PM; Schön A; Bamberg F; Haug A; Dürr EM; Rauch B; Trumm CT; Jakobs TF; Helmberger TK; Reiser MF; Kolligs FT
    Cardiovasc Intervent Radiol; 2012 Feb; 35(1):105-16. PubMed ID: 21431970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeated Treatment with
    Filippi L; Di Costanzo GG; Tortora R; Pelle G; Cianni R; Schillaci O; Bagni O
    Cancer Biother Radiopharm; 2019 May; 34(4):231-237. PubMed ID: 30758985
    [No Abstract]   [Full Text] [Related]  

  • 8. Yttrium-90 Radiation Segmentectomy of Hepatocellular Carcinoma: A Comparative Study of the Effectiveness, Safety, and Dosimetry of Glass-Based versus Resin-Based Microspheres.
    Villalobos A; Arndt L; Cheng B; Dabbous H; Loya M; Majdalany B; Bercu Z; Kokabi N
    J Vasc Interv Radiol; 2023 Jul; 34(7):1226-1234. PubMed ID: 36958669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Resin Microsphere Y90 Dosimetry in Predicting Objective Tumor Response, Survival and Treatment Related Toxicity in Surgically Unresectable Colorectal Liver Metastasis: A Retrospective Single Institution Study.
    Sankhla T; Cheng B; Nezami N; Xing M; Sethi I; Bercu Z; Brandon D; Majdalany B; Schuster DM; Kokabi N
    Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrahepatic Cholangiocarcinoma Treated with Transarterial Yttrium-90 Glass Microsphere Radioembolization: Results of a Single Institution Retrospective Study.
    Gangi A; Shah J; Hatfield N; Smith J; Sweeney J; Choi J; El-Haddad G; Biebel B; Parikh N; Arslan B; Hoffe SE; Frakes JM; Springett GM; Anaya DA; Malafa M; Chen DT; Chen Y; Kim RD; Shridhar R; Kis B
    J Vasc Interv Radiol; 2018 Aug; 29(8):1101-1108. PubMed ID: 30042074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Yttrium-90 Radioembolization in Intrahepatic Cholangiocarcinoma: A Multicenter Retrospective Analysis.
    Buettner S; Braat AJAT; Margonis GA; Brown DB; Taylor KB; Borgmann AJ; Kappadath SC; Mahvash A; IJzermans JNM; Weiss MJ; Lamarca A; Bell JK; Valle JW; Hagendoorn J; Koerkamp BG; Sze DY; Lam MGEH
    J Vasc Interv Radiol; 2020 Jul; 31(7):1035-1043.e2. PubMed ID: 32473757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioembolization with Yttrium-90 Glass Microspheres as a First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma-A Prospective Feasibility Study.
    Kis B; Shridhar R; Mhaskar R; Gyano M; Frakes JM; El-Haddad G; Choi J; Kim RD; Hoffe SE
    J Vasc Interv Radiol; 2023 Sep; 34(9):1547-1555. PubMed ID: 37210030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres.
    Demirelli S; Erkilic M; Oner AO; Budak ES; Gunduz S; Ozgur O; Bozcuk H; Sindel HT; Boz A
    Nucl Med Commun; 2015 Apr; 36(4):340-9. PubMed ID: 25563137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET response criteria for solid tumors predict survival at three months after intra-arterial resin-based 90Yttrium radioembolization therapy for unresectable intrahepatic cholangiocarcinoma.
    Camacho JC; Kokabi N; Xing M; Schuster DM; Kim HS
    Clin Nucl Med; 2014 Nov; 39(11):944-50. PubMed ID: 25140563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of tumour dose response threshold and implication on survival in patients with HCC treated with Y90 radiation segmentectomy: a simple semi-quantitative analysis.
    Cheng B; Sethi I; Villalobos A; Wagstaff W; Schuster DM; Bercu Z; Brandon D; Kokabi N
    Nucl Med Commun; 2021 Aug; 42(8):892-898. PubMed ID: 33795611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: survival, efficacy, and safety study.
    Rafi S; Piduru SM; El-Rayes B; Kauh JS; Kooby DA; Sarmiento JM; Kim HS
    Cardiovasc Intervent Radiol; 2013 Apr; 36(2):440-8. PubMed ID: 22956045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis.
    Al-Adra DP; Gill RS; Axford SJ; Shi X; Kneteman N; Liau SS
    Eur J Surg Oncol; 2015 Jan; 41(1):120-7. PubMed ID: 25449754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results.
    Garin E; Lenoir L; Rolland Y; Edeline J; Mesbah H; Laffont S; Porée P; Clément B; Raoul JL; Boucher E
    J Nucl Med; 2012 Feb; 53(2):255-63. PubMed ID: 22302962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept.
    Garin E; Lenoir L; Edeline J; Laffont S; Mesbah H; Porée P; Sulpice L; Boudjema K; Mesbah M; Guillygomarc'h A; Quehen E; Pracht M; Raoul JL; Clement B; Rolland Y; Boucher E
    Eur J Nucl Med Mol Imaging; 2013 Jul; 40(7):1057-68. PubMed ID: 23613103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-FDG PET independently predicts survival in patients with cholangiocellular carcinoma treated with 90Y microspheres.
    Haug AR; Heinemann V; Bruns CJ; Hoffmann R; Jakobs T; Bartenstein P; Hacker M
    Eur J Nucl Med Mol Imaging; 2011 Jun; 38(6):1037-45. PubMed ID: 21308371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.